Mesothelioma | Tumor

Expansion of IOA-244 Trial Fully Enrolled for Uveal Melanoma

November 26th 2021

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Imfinzi-Chemo Combo Improves Survival for Mesothelioma

November 16th 2021

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.

Opdivo May Improve Survival in Mesothelioma That Progressed on First-Line Chemotherapy

October 26th 2021

Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.

COVID-19 Increases Death, Hospitalization Rates in Patients With Mesothelioma

September 20th 2021

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

Surgery After Radiotherapy May Improve Outcomes in Patients with Malignant Pleural Mesothelioma

August 26th 2021

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in centers with substantial surgical experience.

Overcoming a Mesothelioma Diagnosis at a Young Age

April 12th 2021

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

FDA’s Approval of Opdivo-Yervoy for Unresectable Malignant Pleural Mesothelioma was ‘Desperately Needed’, But Questions Remain

October 20th 2020

The FDA’s approval or Opdivo (nivolumab) and Yervoy (ipilimumab) for the frontline treatment of patients with unresectable malignant pleural mesothelioma was desperately needed, says a thoracic oncologist at Memorial Sloan Kettering Cancer center. However, some questions remain.

FDA Approves Opdivo-Yervoy Combo for Unresectable Malignant Pleural Mesothelioma

October 2nd 2020

The Food and Drug Administration’s approval of Opdivo in combination with Yervoy for patients with unresectable malignant pleural mesothelioma marks the first new systemic therapy approved in more than 15 years in this setting.

CURE's Clinical Trial Corner: Mesothelioma Edition

November 25th 2019

Here is a list of clinical trials that are currently happening within the mesothelioma space.

Friday Frontline: Cancer Updates, Research and Education on November 22, 2019

November 22nd 2019

From plans to sue the School District of Philadelphia over a mesothelioma diagnosis to Dwayne “The Rock” Johnson singing for a 3-year-old with acute lymphoblastic leukemia, here’s what is making headlines in the cancer space this week.

Scientists See Potential in Cellular "Death by Iron" for Cancer Treatment

October 19th 2019

The same properties that make certain cancers hard to treat may also promote their death by ferroptosis, scientists at the Sloan Kettering Institute have found.

Fighting the Uncertainty of Cancer With Self-Education

October 11th 2019

A seven-year mesothelioma survivor encourages patients with cancer to be their own advocate.

The Role of Immunotherapy in Treating Mesothelioma

October 11th 2019

A phase 3 trial compared Keytruda versus chemotherapy for patients with advanced pretreated malignant pleural mesothelioma.

Investigational Drug Shows Response in Patients with Malignant Pleural Mesothelioma

September 20th 2019

Cediranib combined with platinum-based chemotherapy helped patients live longer than placebo.

Addressing Diet and Nutrition in Patients With Mesothelioma

August 12th 2019

A registered dietician discussed the importance of maintaining one’s weight while going through treatment for mesothelioma.

Past, Present and Future: How Far We've Come With Mesothelioma

July 29th 2019

CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.

Mesothelioma: Symptoms and Risk Factors To Be Aware Of

July 26th 2019

CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors.

Study Results Fail to Support Routine Use of Prophylactic Irradiation in Mesothelioma

June 19th 2019

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

CAR Therapy for Solid Tumors Draws Attention at Annual Cancer Conference

June 18th 2019

Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.

Patients with Mesothelioma See No Survival Benefit With Defactinib Maintenance Therapy

June 18th 2019

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

FDA Approves First Malignant Pleural Mesothelioma Therapy in Over 15 Years

May 24th 2019

The Food and Drug Administration has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the front-line treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

Plural Immunotherapy

June 22nd 2018

An immunotherapy pair looks promising for those with pleural mesothelioma, which is now treated with chemotherapy.

Immunotherapy Shows Promise for Mesothelioma Treatment

November 10th 2017

Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.

Mesothelioma and My Fight to Live

April 12th 2017

On a Mission: Mesothelioma Survivor Fights for Awareness, Understanding and Hope

April 5th 2017

After a shocking diagnosis, Heather Von St. James is on a mission to spread awareness about mesothelioma.

Immunotherapies Show Promise in Mesothelioma, Small Cell Lung Cancer

November 19th 2015

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer (SCLC) and mesothelioma, two aggressive thoracic malignancies with few options.

NCI to Fulfill "Ongoing Dream" With 20-Arm Precision Oncology Trial

June 4th 2015

An ambitious clinical trial set to start in July will match patients to treatments based on molecular abnormalities, rather than cancer types, testing 20 targeted drugs at once.

Rare Finds: A Rare Cancer Diagnosis

November 24th 2014

Finding specialized care is worth the effort for patients with uncommon cancers.

Letters from Our Readers

March 16th 2007

Readers respond to past CURE articles on living with mesothelioma, hospice, beating bladder cancer, lung cancer, and response to CURE's 2007 Cancer Resource Guide.

Fatal Fibers

September 27th 2006

Asbestos exposure is the main cause of mesothelioma, accounting for more than 80 percent of cases.